Targeting a specific protein to improve treatment for pancreatic cancer
Targeting PYK2 for the treatment of PDAC
This study is looking at a protein called PYK2 that is found in high amounts in a type of pancreatic cancer called PDAC, and the goal is to find new ways to treat this tough cancer by understanding how PYK2 helps it grow.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-10746761 on NIH RePORTER |
What this research studies
This research focuses on pancreatic ductal adenocarcinoma (PDAC), a highly lethal form of cancer with a very low survival rate. The study aims to identify and target a protein called PYK2, which is found at elevated levels in PDAC tissues, to develop new therapeutic strategies. By understanding how PYK2 contributes to cancer progression, the researchers hope to create effective treatments that can improve patient outcomes. The approach involves both laboratory studies and potential future clinical applications.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with pancreatic ductal adenocarcinoma, particularly those with advanced disease.
Not a fit: Patients with other types of cancer or those without pancreatic ductal adenocarcinoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly extend survival for patients with pancreatic cancer.
How similar studies have performed: While targeting KRAS has been challenging, there is growing interest in similar approaches targeting downstream effectors like PYK2, indicating potential for success in this novel area.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Hu, Jing — University of Pittsburgh at Pittsburgh
- Study coordinator: Hu, Jing
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.